Published in Blood on July 19, 2010
Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis (EpiCardiAL) | NCT01511263
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis | NCT04392960
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Al amyloidosis. Orphanet J Rare Dis (2012) 1.29
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica (2012) 1.10
Update on treatment of light chain amyloidosis. Haematologica (2014) 1.00
Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev (2015) 0.96
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica (2013) 0.92
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood (2012) 0.86
Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant (2013) 0.85
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica (2013) 0.85
Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias. Clin J Am Soc Nephrol (2016) 0.81
Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis. J Geriatr Cardiol (2014) 0.78
Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases. Case Rep Med (2014) 0.78
Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies. Clin Med Insights Cardiol (2015) 0.77
Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study-A Single-Center, Blinded, Randomized Controlled Trial. Clin Cardiol (2016) 0.76
Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ Involvement. J Clin Med Res (2015) 0.75
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009. Bone Marrow Transplant (2016) 0.75
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia (2016) 0.75
Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart (2017) 0.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med (2014) 3.92
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J (2004) 2.87
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
A primer of amyloid nomenclature. Amyloid (2007) 2.70
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol (2006) 2.56
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood (2004) 2.52
Noncooperative interactions between transcription factors and clustered DNA binding sites enable graded transcriptional responses to environmental inputs. Mol Cell (2010) 2.43
Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2004) 2.43
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J (2008) 2.29
Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood (2011) 2.29
Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. Br J Haematol (2013) 2.28
Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med (2007) 2.27
Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Atrial fibrillation after isolated coronary surgery affects late survival. Circulation (2008) 2.02
Significance of total and differential leucocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty. Eur Heart J (2006) 1.99
Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol (2008) 1.97
Clinical evaluation of defibrillation testing in an unselected population of 2,120 consecutive patients undergoing first implantable cardioverter-defibrillator implant. J Am Coll Cardiol (2012) 1.95
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J (2005) 1.95
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 1.93
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation (2003) 1.93
Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid (2010) 1.91
Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid (2014) 1.91
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis (2006) 1.88
Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol (2007) 1.85
Are we not over-estimating the prevalence of coeliac disease in the general population? Ann Med (2010) 1.84
International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation (2004) 1.77
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J (2012) 1.77
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol (2002) 1.76
Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med (2007) 1.75
Anemia of chronic disease and defective erythropoietin production in patients with celiac disease. Haematologica (2008) 1.72
Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol (2008) 1.71
Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol (2005) 1.69
Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis (2013) 1.68
Failure of implantable cardioverter-defibrillator leads: a matter of lead size? Heart Rhythm (2012) 1.68
Nutritional parameters associated with prolonged hospital stay among ambulatory adult patients. CMAJ (2010) 1.65
Evaluation of friction of stainless steel and esthetic self-ligating brackets in various bracket-archwire combinations. Am J Orthod Dentofacial Orthop (2003) 1.63
Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. J Hypertens (2006) 1.61
Evaluation of friction of conventional and metal-insert ceramic brackets in various bracket-archwire combinations. Am J Orthod Dentofacial Orthop (2003) 1.60
Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis (2012) 1.59
Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J (2006) 1.58
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood (2011) 1.58
Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta (2005) 1.58
Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery. Ann Thorac Surg (2007) 1.55
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica (2006) 1.53
Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. J Pediatr Gastroenterol Nutr (2003) 1.52
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol (2012) 1.51
In-vitro fluoride release rates from 9 orthodontic bonding adhesives. Am J Orthod Dentofacial Orthop (2007) 1.50
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood (2007) 1.48
Accuracy and usefulness of fusion imaging between three-dimensional coronary sinus and coronary veins computed tomographic images with projection images obtained using fluoroscopy. Europace (2009) 1.48
Adipokines, hormonal parameters, and cardiovascular risk factors: similarities and differences between patients with erectile dysfunction of arteriogenic and nonarteriogenic origin. J Sex Med (2012) 1.44
Prognostic relevance of a non-invasive evaluation of right ventricular function and pulmonary artery pressure in patients with chronic heart failure. Eur J Heart Fail (2013) 1.44
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44
Identification of a lower grade muconodular subtype of gastric mucinous cancer. Virchows Arch (2004) 1.43
Sustained improvement in left ventricular function after bone marrow derived cell therapy in patients with acute ST elevation myocardial infarction. A 5-year follow-up from the Stem Cell Transplantation in Ischaemic Myocardium Study. Swiss Med Wkly (2012) 1.43
Impact of lesion sets on mid-term results of surgical ablation procedure for atrial fibrillation. J Am Coll Cardiol (2011) 1.43
Prognostic value of circulating CD34+ cells in myelodysplastic syndromes. Leuk Res (2008) 1.42
Feasibility and acute efficacy of radiofrequency ablation of cavotricuspid isthmus-dependent atrial flutter guided by real-time 3D TEE. JACC Cardiovasc Imaging (2011) 1.42